Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Mitsubishi Chemical Holdings Plans Organizational Rejig in April, Ueno to Helm Pharma Unit
January 11, 2022
- Kissei/Maruishi’s Pruritus Drug Hits Mark in Japan PIII Study
January 11, 2022
- Rexulti Expands Label into Pediatric Schizophrenia in US
January 11, 2022
- Sosei Inks GPCR Strategic Collaboration with Google’s Verily
January 11, 2022
- Takecab Tops Japan Sales Ranking in December: Encise
January 11, 2022
- Riken Genesis’s AmoyDx Now Available as CDx for Takeda’s ALK Inhibitor Alunbrig
January 7, 2022
- Eisai Awards Exclusive Rights for Splicing Modulator H3B-8800 to Roivant
January 7, 2022
- Opdivo Gets Adjuvant Nod for Esophageal Cancer in Taiwan: Ono
January 6, 2022
- Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag
January 6, 2022
- Detailing Activities Rise in All Promotion Channels MOM, YOY in November: Intage
January 6, 2022
- Nexium and Feburic Generic Debuts Eyed in 2022, but with Caution to Avoid Shortages
January 5, 2022
- Nobelpharma, VLP Therapeutics Ink MOU for Malaria/Dengue Vaccine Collaboration
January 5, 2022
- Daiichi Sankyo’s EZH1/2 Inhibitor Filed for ATL in Japan
January 5, 2022
- 5 Atopic Dermatitis Drugs Debut in Japan since 2018; Focus Now on Roles of Dupixent, JAK Inhibitors
December 28, 2021
- Chugai Joins NCC Study for Asia-Prevalent Cancers
December 28, 2021
- Shionogi Gets Commercial Rights to Susmed’s Insomnia App
December 28, 2021
- Shionogi Launches Global PIII for COVID-19 Vaccine
December 28, 2021
- Daiichi Sankyo’s HER3 ADC Gets Breakthrough Therapy Tag in US
December 27, 2021
- Sosei Gets US$100 Million from Neurocrine as Deal Clears Antitrust Hurdles
December 27, 2021
- Daiichi Sankyo Kicks Off PIII for Enhertu in Frontline NSCLC
December 27, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…